The predictive value of anti-CCP3 for US subclinical synovitis development was also observed when the multivariable analysis was carried out excluding high-level anti-CCP2 [anti-CCP3 OR 3.60 (95% CI 1.74, 7.44), P < 0.01] or RF [anti-CCP3 OR 5.64 (95% CI 2.50, 12.76), P < 0.01] (Supplementary Table S1, available at Rheumatology online). This evidence concerns the gene AGBL2 and synovitis.